Susan Dent, MD
Co-Chair, Global Cardio-Oncology Summit; Founder, Canadian Cardiac Oncology Network; Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, ON
Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Associate Professor in the Department of Medicine at the University of Ottawa. She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group.Read More...
Presently, she is a member of Cancer Ontario Breast Disease Site Group Practice Guidelines Committee, IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group and Grant Review Panel member for the Canadian Institute of Health Research. Her areas of interest include breast cancer, treatment toxicities and cardiotoxicity. She is the founder of the Ottawa Cardiac Oncology Program as well as the Canadian Cardiac Oncology Network, organizations dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.
Daniel Lenihan, MD
Co-Chair, Global Cardio-Oncology Summit; President, International CardiOncology Society - North America; Professor of Medicine; Director, Clinical Research Program, Vanderbilt Heart and Vascular Institute, Nashville, TN
Dr. Lenihan, has been active in clinical research in cardiology, and specifically in heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.Read More...
His current projects include early phase clinical trials in heart failure, including the recently presented Phase 1 trial of GGF2 in cooperation with Acorda, Inc. As the Director of Clinical Research in the Division of Cardiovascular Medicine, Dr Lenihan is managing over 100 clinical trials in conjunction with all of VHVI faculty and continues to enhance and foster collaboration among a host of colleagues both internally and throughout the world. He is the current president (US/Canada) of the International CardiOncology Society, a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Greg Armstrong, MD
Pediatric Oncologist, St. Jude Children's Research Hospital, Memphis TN
Greg Armstrong MD, MSCE is the Principal Investigator of the Childhood Cancer Survivor Study (CCCS). The CCSS is a multi-institutional, collaborative cohort study initiated in 1994, which has successfully established and followed a cohort of 14,370 five-year survivors of childhood cancer diagnosed between1970-1986 and a population of sibling controls.Read More...
The cohort, derived through 26 original participating clinical centers, has collected detailed information on cancer diagnosis, therapy received, and outcomes encompassing over 248,000 person-years of follow-up. Under the leadership of Dr. Armstrong and Dr. Melissa Hudson, CCSS Co-PI the CCSS is expanding the cohort to include an additional 10,000 survivors diagnosed between 1987-1999. In addition to maintaining a clinical practice in both pediatric neuro-oncology and pediatric cancer survivor care, Dr. Armstrong, co-chairs the St. Jude Lifetime Cohort (SJLIFE) Cardiopulmonary Working Group and has published many of the early cardiac outcomes within the SJLIFE cohort. He currently holds an RO1 that is evaluating novel echocardiography endpoints (myocardial strain) for early detection of cardiomyopathy, within the SJLIFE population.
Christine Brezden-Masley, MD, PhD
Medical Oncologist, St. Michael’s Hospital, Toronto, ON
Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Division Head of Hematology / Oncology at St. Michael’s Hospital in Toronto and is the Head of the Oncology Clinical Research Group there. She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Assistant Professor at the University of Toronto.Read More...
She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region. She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research. Her main area of clinical research is cardiotoxicity from cancer therapy and is the Co-Chair of the annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is active in research, education and has been instrumental in the clinical development of the cancer program at St. Michael’s Hospital.
Joseph Carver, MD
Bernard Fishman Clinical Professor of Medicine; Chief of Staff; and Director of Penn Cardiology Fellow's Practice, Abramson Cancer Center of the University of Pennsylvania; Senior Administrative Officer, Abramson Family Cancer Research Institute, Philadelphia, PN
Dr. Joseph Carver is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program.Read More...
From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. His clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012.
R. Frank Cornell, MD
Assistant Professor of Medicine, School of Medicine Vanderbilt University; Hematologist/Oncologist, Vanderbilt University Medical Centre, Nashville, TN
Dr. Cornell is an assistant professor of medicine. He received a B.S. in clinical laboratory science from Saint Louis University and then worked in clinical and molecular hematology at Johns Hopkins Hospital. He attended medical school at Trinity College in Dublin, Ireland. Dr. Cornell then completed his Internal Medicine Residency and Hematology/Oncology Fellowship at The Medical College of Wisconsin.Read More...
He is currently obtaining his Master's in Clinical and Translational Science. He specializes in the treatment of plasma cell disorders including Multiple Myeloma, Smoldering Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), POEMS syndrome, Amyloid Light-Chain (AL) Amyloidosis, Plasma Cell Leukemia, Solitary Plasmacytoma and Waldenstrom Macroglobulinemia. Dr. Cornell's research focuses on translational and early phase clinical trials for the treatment of multiple myeloma. He also conducts research and clinical trials for relapsed and/or refractory multiple myeloma. Dr. Cornell is an active member of the American Society of Hematology, American Society of Clinical Oncology, and the American Society for Blood and Marrow Transplantation. He is a member of the multiple myeloma
Kathryn Culos, PharmD, BCOP
Adult Stem Cell Transplant Clinical Pharmacist, Vanderbilt University Medical Centre, Nashville, TN
Kathryn Culos is a Board Certified Oncology Pharmacist and the Adult Stem Cell Transplant Clinical Pharmacist at Vanderbilt University Medical Center in Nashville, Tennessee. She received her Doctorate of Pharmacy from the University of Illinois at Chicago College of Pharmacy. She went on to complete her pharmacy practice and oncology pharmacy residency at The University of Illinois Hospital and Health Sciences Center. During residency Dr. Culos focused her research on the efficacy and toxicity of melphalan in multiple myeloma stem cell transplant patients with renal dysfunction as well as the prescribing and administration of oral chemotherapy.Read More...
Her current research continues in the outcomes of stem cell transplant patients with renal and hepatic dysfunction, co-authoring a literature analysis and recommendations for stem cell transplant preparative regimen dosing in patients with chronic hepatic dysfunction. Dr. Culos is also currently investigating the impact of pharmacogenomics with calcineurin inhibitors in allogeneic transplant patients.
Giuseppe Curigliano, MD, PhD
Medical Oncologist; Director of the Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy
Giuseppe Curigliano, MD, PhD, is Chair of the Division of Early Drug Development at the European Institute of Oncology, in Milan, Italy, where besides his clinical work, he is a clinician and researcher specializing in breast cancer. Dr. Curigliano earned his MD at the Universita’ Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa.Read More...
He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection. He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 3 years in the phase I unit, contributing to the successful development of several targeted agents and cytotoxics. Since 2001 he is an assistant professor of Clinical Pharmacology at University of Milan. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of the Division of Clinical Oncology coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). His clinical experience is based on a daily clinical management of patients with solid tumours, within a comprehensive cancer center accepting every year at least 85.000 first diagnosis patients. He practices in the in-patient, out-patient and day-hospital setting. He served for 3 years on emergency and palliative care section of the Division. He is an active member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He serves on the Clinical Research Committee of the AIOM. He serves as a faculty member in the European School of Oncology (ESO). He is a member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is an ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference 2013 and served ad Chair of the metastatic breast cancer track for ESMO 2014 meeting in Madrid. Dr. Curigliano’s research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development in breast cancer at the European Institute of Oncology. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 160 peer reviewed article, most of them as first author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute, the European Journal of Cancer and many other “breast oriented journals”. He is member of the Editorial Board of Journal of Clinical Oncology and Annals of Oncology. He serves in the press committee of the European Society of Medical Oncology as Spokesperson coordinator for breast cancer.
Michael J. Fisch, MD
Chair, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, TX
Dr. Fisch is Professor and Chair of the Department of General Oncology in the Division of Cancer Medicine at MD Anderson Cancer Center. He is the Principal Investigator of the MD Anderson Community Clinical Oncology Program (CCOP) Research Base, and this became the starting point for a newly developed Department of General Oncology led by Dr. Fisch since 2008.Read More...
In addition, Dr. Fisch has served as Chair of the ECOG Symptom Management Committee (since 2006), and Co-Chair of the NCI Symptom Management and Quality of Life Committee (since 2007). He is a member of ICOS and has pursued cardio-oncology clinical research that bridges the academic and community oncology settings.
Clinical Nurse Specialist, Oncology Program, Health Science Centre, Winnipeg, MB
Darlene Grantham is an Oncology Clinical Nurse Specialist at Health Sciences Centre, Winnipeg, Manitoba. Darlene also holds a Bioethics Certificate through the Provincial Health Ethics Network, Alberta, Canada. She maintains Canadian Nursing Association (CNA) certifications in Hospice and Palliative Care and Oncology Nursing.Read More...
Darlene is working with the Cardiac Clinical Nurse Specialist and they have developed a Cardio-Oncology Database, and a Nursing Cardiac Complications of Cancer Therapy Clinical Practice Guideline which will be trialed on the Leukemia/Bone Marrow Transplant Unit In the New Year. Other active research study projects include; Advance Care Planning: the Cancer Patient’s Perspective, Responding to Moral Distress Associated with working on an Acute Leukemia/Bone Marrow Transplant Units: A Team Perspective and Evaluating Patient Satisfaction on an Acute Leukemia/Bone Marrow Transplant Day/Night Area.
Eric Harrison, MD
Medical Director, Tampa Memorial Hospital;, Cardiologist, Harrison Cardiovascular Centre, Tampa, FL
Dr. Harrison is currently the National Director of Advanced Cardiac Imaging of Iasi Healthcare Inc . which owns and operates 15 acute care hospitals in Florida, Texas, Louisiana, Utah, Arizona, and Nevada. Dr. Harrison was one of first to use the therapeutic hypothermia for Cardiac Arrest patients. He began to use this treatment clinically shortly after the landmark articles were published in February 2002.Read More...
He is currently integrating hypothermic medicine into the IASIS healthcare system. He has served as a consultant for many national companies associated with cardiac imaging. Dr. Harrison started and directs the Joint Memorial Hospital / University of South Florida Medical School Advanced Cardiac Imaging Program for practicing physicians , cardiac fellows, and medical student training. He is a preceptor for the University of South Florida Medical School and Saba University Medical School of the Netherland Antilles. Dr. Harrison received his medical degree from the University of Kentucky and completed internship, Internal Medicine residency and Cardiology Fellowship at the University of South Florida where he was a Special Fellow of the Florida Heart Association. He was acting Director of the Cath Lab at the VA Hospital for 3 month prior to finishing his training. He is a founding physician of the University of South Florida Medical School. Dr. Harrison's experience in cardiology covers a broad spectrum. He was co-director of the Cardiology Center at Tampa General Hospital for thirteen years and directed noninvasive cardiology for seven years where he started echocardiography and nuclear cardiology. At Tampa General he performed over 14,000 heart catheterizations, numerous coronary angioplasties, cardiac electrophysiologic studies and myocardial biopsies and was a transplant cardiologist on the transplant team for three years. His first transplant patient has survived over 20 years. He and his colleagues started the first outpatient cardiovascular health center in Tampa at Memorial Hospital where he is currently the Medical Director and where he has directed the cardiac rehabilitation program. His non-invasive cardiology interests are 3D echo, multislice CAT scan imaging of the coronaries, Cardiac PET/CT, Cardiac MRI, and hybrid imaging.
Javid Moslehi, MD
Director, Vanderbilt Cardio-Oncology, Vanderbilt University Medical Centre, Nashville, TN
Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital.Read More...
Following the completion of clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis (formation of new blood vessels) in heart disease. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School with a clinic and research program focused on the cardiovascular care for cancer patients and cancer survivors. In 2014, he joined Vanderbilt. Dr. Moslehi is an expert clinician on the management of cardiac complications associated with radiation and both novel and traditional chemotherapies. His clinic and research program is focused on the mechanisms of toxicities associated with novel targeted therapies and how this knowledge can be modulated to understand human cardiovascular biology.
Jeffrey Sulpher, MD
Medical Oncologist, The Ottawa Hospital Cancer Centre, Ottawa, ON
Dr. Jeffrey Sulpher received his BSc.(Hons.) in Biopharmaceutical Sciences from the University of Ottawa in 2003, and his M.D. from Queen's University in 2008. He went on to complete his internal medicine and medical oncology residencies at the University of Ottawa. He is currently a cardiac oncology fellow at the Ottawa Hospital Cancer Centre.Read More...
His current research projects include the investigation of biomarkers for identification of patients at risk of treatment-induced cardiotoxicity, as well as a national physician's survey exploring issues surrounding cardiac oncology in Canada.
S. Kishore Thain, MD
Radiation Oncologist, Cancer Centre of Southeastern Ontario, Kingston, ON
Dr. Thain is a Radiation Oncologist at the Cancer Center of Southeastern Ontario and an Assistant Professor at Queen's University in Kingston, Ontario. He completed his specialist training in the UK. His areas of interest include breast cancer, lung cancer, CNS tumors and prevention of cardiotoxicity. He is the Chair of the CNS Tumor Multidisciplinary Group and Co-Chair of the Breast Cancer Multidisciplinary Group in the region.Read More...
He has co-authored several guidelines, including "Clinical Practice Guidelines for the Care and Treatment of Breast Cancer", CMAJ, 1998; "Questions and Answers on Breast Cancer for Women and their Physicians", CMAJ, 1998; and "Questions and Answers on Breast Cancer for Women and their Physicians", 2nd Ed, 2001.
Sean Virani, MD
Cardiologist, Vancouver General Hospital, Vancouver, BC
Dr. Virani is a key opinion leader in heart failure in Canada. He is founding Director of the Heart Failure and Cardiology-Oncology Programs at Vancouver General Hospital, Regional Director of Heart Failure Services for Vancouver Coastal Health/Providence Health Care and Clinical Assistant Professor of Medicine at the University of British Columbia.Read More...
He completed his internal medicine and cardiology training at UBC before embarking on a subspecialization in heart failure and cardiac transplantation at Stanford University. He also has a Master’s degree in Public Health from Columbia University with a focus on healthcare management. His professional interests include public policy related to health care delivery with specific reference to access, capacity and quality in the Canadian context. Dr. Virani has authored a number of papers on chronic and acute decompensated heart failure and is a principal investigator on numerous research trials. He holds peer reviewed grant funding as a principal or co-investigator in excess of $1 million. He serves on the Provincial Advisory Panel for Heart Failure, the executive of the Canadian Heart Failure Society, the Canadian Heart Failure Guidelines Committee and chairs the Ministry of Health/BCMA Practice Support Program for Heart Failure.